Teachers Advisors’s VYNE Therapeutics VYNE Stock Holding History

Teachers Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$97K	Hold	171	–	–	﹤0.01%	2936
2018 Q4	$51K	Hold	171	–	–	﹤0.01%	2987
2018 Q3	$121K	Sell	171 -2	-1%	-$1.24K	﹤0.01%	2996
2018 Q2	$101K	Hold	173	–	–	﹤0.01%	3043
2018 Q1	$469K	Buy	+173	New	+$421K	﹤0.01%	2551

Other funds holding VYNE

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Teachers Advisors's VYNE Position: Q1 2019 in Review

Teachers Advisors held its VYNE Therapeutics (VYNE) position steady in Q1 2019 at 171 shares worth $97K. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Teachers Advisors first reported a position in VYNE in Q1 2018 and has held it in 5 quarters since. The position peaked at $469K in Q1 2018. 59 funds tracked by Wall St. Rank hold VYNE as of Q1 2019.

Teachers Advisors held 171 shares of VYNE Therapeutics worth $97K as of Q1 2019.
Teachers Advisors left its VYNE Therapeutics share count unchanged in Q1 2019.
VYNE Therapeutics made up ﹤0.01% of Teachers Advisors's portfolio in Q1 2019, its #2936 holding.
Teachers Advisors first reported a position in VYNE Therapeutics in Q1 2018 and has held it in 5 quarters since.
Teachers Advisors's VYNE Therapeutics position peaked at $469K in Q1 2018.
59 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2019.

Based on Teachers Advisors's 13F filing for Q1 2019, filed 14 May 2019.